|
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Breakthrough: Surgeons Restore Sight to Certain Blind Patients Using Their Own Stem Cells"Our first trial in four patients showed that CALEC was safe and the treatment was possible. Now we have this new data supporting that CALEC is more than 90% effective at restoring the cornea's surface, which makes a meaningful difference in individuals with cornea damage that was considered untreatable." -Professor Ula Jurkunas, principal investigator
Researchers at Massachusetts Eye and Ear, a specialty hospital located in Boston, have developed cultivated autologous limbal epithelial cells (CALEC) and it has become the first stem cell therapy for the eye ever trialed in the United States. The ground-breaking procedure starts by removing stem cells from a healthy eye with a biopsy. Then they are grown for two to three weeks before being surgically transplanted onto an injured cornea. In a clinical trial, 14 patients with "irreversible" damage to their cornea, or the outermost layer of the eye, saw restoration in the first 18 months. The patients in the trial could only have one eye that needed treatment because the other healthy eye was used for the biopsy. According to a press release from Massachusetts Eye and Ear, when a person suffers a cornea injury, such as a chemical burn, infection, or other trauma, it can deplete the limbal epithelial cells, which can never regenerate. As a result, the eye sustains permanent surface damage and can't undergo a corneal transplant, which is the current standard of care for vision rehabilitation. People with these injuries often experience persistent pain and visual difficulties. "Our first trial in four patients showed that CALEC was safe and the treatment was possible," said principal investigator Professor Ula Jurkunas. "Now we have this new data supporting that CALEC is more than 90% effective at restoring the cornea's surface, which makes a meaningful difference in individuals with cornea damage that was considered untreatable." According to Massachusetts Eye and Ear, CALEC completely restored the cornea in 50% of participants at their 3-month visit, and that rate of complete success increased to77%and79%at their 12- and 18-month visits, respectively. Two participants met the definition of partial success at 12 and 18 months and the overall success of CALEC was 92% and 93% at 12 and 18 months. Three participants received a second CALEC transplant, one of whom reached complete success by the study end visit. An additional analysis of CALEC's impact on vision showed varying levels of improvement in visual acuity in all 14 CALEC patients. There was only one major adverse effect to the treatment. A bacterial infection occurred in one patient eight months after the implant due to their "chronic" contact lens use. The CALEC trial is the first human study of a stem cell therapy funded by the National Eye Institute (NEI), which is a part of the National Institutes of Health (NIH). Additionally, it is the first stem cell therapy in the eye in the US. Currently, CALEC remains an experimental procedure and is not offered at Massachusetts Eye and Ear or any US hospital. Additional studies will be needed before the treatment is submitted for federal approval. "We feel this research warrants additional trials that can help lead towards FDA approval," said Jurkunas. "While we are proud to have been able to bring a new treatment from the lab bench to clinical trials, our guiding objective was and always will be for patients around the country to have access to this effective treatment." Subscribe for free to Breaking Christian News here
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Other Recent Articles from Breaking Christian News Should Christians Vote? Longtime Bible Teacher Steve Gregg Gave This Excellent Answer... Watch: JD Vance Turns to Prayer as Medical Emergency Halts Rally FBI: Powerful Virginia Democrat Arrested on Drug, Racketeering, Money Laundering Charges FBI Stops Alleged ISIS Plot to Kill Texas Congressman Polling Scandal Rocks the Midterms, Fueling More Skepticism about the Media's Lopsided Projections What's In a Name? Perhaps the Truth. DOJ Court Filing Disputes Rep. Ilhan Omar's Name 8-1 Supreme Court Decision Upends Student ID Fight in Battleground Days Before Key Senate Election First Lady Melania Trump Brokers Ukraine-Russia Temporary Ceasefire Archeologist Believes His Team Has Confirmed the Site of Jesus' Baptism Small Business Administration's Million Dollar Pitch Competition House Committee Report Details 'Dangerous Consequences' of Sanctuary County's Soros-Backed Attorney New Migrant Caravan Leaves Southern Mexico in Hopes for Democrat Win in Midterms US Supreme Court Allows Prisoner Transgender Operations at Taxpayer Expense Prayer Alert: The Discovered and Exposed Real Coup Plan in America Donnie Wahlberg Praises God After Private Jet Runs Off Las Vegas Runway Prayer Alert: Calvary Chapel Pastor and Wife Killed Outside Home, Leaving 2 Teenage Children Alberta Votes to Remain in Canada But Take More Control from Carney Gov't Inside the Secret Democrat Plot to Weaponize Congress Against Elon Musk Senate Showdown: Jews, Muslims and the Fight for Michigan Search the Articles Archives |
All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.
Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved
Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.
| Home | Store | Subscribe | Facebook | Article Archive |